{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T23:28:54Z","timestamp":1698362934687},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1994,12,1]],"date-time":"1994-12-01T00:00:00Z","timestamp":786240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Autonomic Research"],"published-print":{"date-parts":[[1994,12]]},"DOI":"10.1007\/bf01821529","type":"journal-article","created":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T14:12:23Z","timestamp":1119881543000},"page":"303-305","source":"Crossref","is-referenced-by-count":4,"title":["Naloxone does not prevent apomorphine-induced emesis or hypotension in dogs"],"prefix":"10.1007","volume":"4","author":[{"given":"J. L.","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Llau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Senard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01821529_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0074-7742(08)60705-9","volume":"19","author":"FC Colpaert","year":"1976","unstructured":"Colpaert FC, Van Bever WFM, Leysen JEMPF. Apomorphine: chemistry, pharmacology, biochemistry.Int Rev Neurobiol 1976;19: 225\u2013268.","journal-title":"Int Rev Neurobiol"},{"key":"BF01821529_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0278-5846(88)90033-4","volume":"12","author":"S Lal","year":"1988","unstructured":"Lal S. Apomorphine in the evaluation of dopaminergic function in man.Prog Neuropsychopharmacol Biol Psychiatry 1988;12: 117\u2013164.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BF01821529_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1472-8206.1993.tb00226.x","volume":"7","author":"AJ Lees","year":"1993","unstructured":"Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine.Fundam Clin Pharmacol 1993;7: 121\u2013128.","journal-title":"Fundam Clin Pharmacol"},{"key":"BF01821529_CR4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00003495-199346030-00005","volume":"46","author":"JL Montastruc","year":"1993","unstructured":"Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management.Drugs 1993;46: 384\u2013393.","journal-title":"Drugs"},{"key":"BF01821529_CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1472-8206.1993.tb00238.x","volume":"7","author":"E Nicolle","year":"1993","unstructured":"Nicolle E, Pollak P, Serre-Debeauvais F, Richard P, Gervason U, Broussolle E, Gavend M. Pharmacokinetics of apomorphine in parkinsonian patients.Fundam Clin Pharmacol 1993;7: 245\u2013252.","journal-title":"Fundam Clin Pharmacol"},{"key":"BF01821529_CR6","first-page":"1","volume-title":"Apomorphine and Other Dopaminomimetics, Vol 1: Basic Pharmacology","author":"JL Neumeyer","year":"1981","unstructured":"Neumeyer JL, Lal S, Baldessarini RJ. Historical highlights of the chemistry, pharmacology and early clinical uses of apomorphine. In: Gessa GL, Corsini GU, eds.Apomorphine and Other Dopaminomimetics, Vol 1: Basic Pharmacology. New York, Raven Press, 1981: 1\u201317."},{"key":"BF01821529_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/00002826-199110000-00009","volume":"14","author":"U Bonucelli","year":"1991","unstructured":"Bonucelli U, Piccini P, Del Dotto P, Rosso G, Corsini GU, Muratorio A. Naloxone partly counteracts apomorphine side effects.Clin Neuropharmacol 1991;14: 442\u2013449.","journal-title":"Clin Neuropharmacol"},{"key":"BF01821529_CR8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00002826-199210000-00009","volume":"15","author":"JL Montastruc","year":"1992","unstructured":"Montastruc JL. Rascol O. Montastruc P. Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression.Clin Neuropharmacol 1992;15: 404\u2013407.","journal-title":"Clin Neuropharmacol"},{"key":"BF01821529_CR9","first-page":"92","volume":"277","author":"JL Montastruc","year":"1985","unstructured":"Montastruc JL, Guiol C, Tran MA, Lhoste F, Montastruc P. Studies on the cardiovascular actions of apomorphine in dogs: central versus peripheral mechanisms and role of the adrenal medulla.Arch Int Pharmacodyn 1985;277: 92\u2013103.","journal-title":"Arch Int Pharmacodyn"},{"key":"BF01821529_CR10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/0024-3205(79)90403-X","volume":"25","author":"J Sawynok","year":"1979","unstructured":"Sawynok J, Pinsky C, Labella FS. On the specificity of naloxone as an opiate antagonist.Life Sci 1979;25: 1621\u20131632.","journal-title":"Life Sci"},{"key":"BF01821529_CR11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00002826-198612000-00010","volume":"9","author":"O Rascol","year":"1986","unstructured":"Rascol O, Montastruc JL. Cardiovascular effects of apomorphine in humans: evidence for peripheral mechanisms.Clin Neuropharmacol 1986;9: 566\u2013569.","journal-title":"Clin Neuropharmacol"},{"key":"BF01821529_CR12","first-page":"13","volume-title":"Apomorphine and Other Dopaminomimetics. Vol 2: Clinical Pharmacology","author":"GU Corsini","year":"1981","unstructured":"Corsini GU, Piccardi MP, Boccheta A, Bernardi F, Del Zompo M. Behavioural effects of apomorphine in man: dopamine receptor implications. In: Corsini GU, Gessa GL, eds.Apomorphine and Other Dopaminomimetics. Vol 2: Clinical Pharmacology. New York: Raven Press, 1981: 13\u201324."},{"key":"BF01821529_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0361-1124(73)80077-2","volume":"2","author":"DS Rautsen","year":"1973","unstructured":"Rautsen DS, Ochs MA. Apomorphine-naloxone controlled rapid emesis.J Am Coll Emerg Physicians 1973;2: 44\u201345.","journal-title":"J Am Coll Emerg Physicians"},{"key":"BF01821529_CR14","first-page":"295","volume":"43","author":"F Mitchelson","year":"1992","unstructured":"Mitchelson F. Pharmacological agents affecting emesis.A review (part 1). Drugs 1992;43: 295\u2013315.","journal-title":"A review (part 1). Drugs"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01821529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01821529\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01821529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T14:39:17Z","timestamp":1557412757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01821529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994,12]]}},"alternative-id":["BF01821529"],"URL":"https:\/\/doi.org\/10.1007\/bf01821529","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,12]]}}}